TOP STORIES
BOEING POSTS STRONG RESULTS, RAISES OUTLOOK AGAIN
Boeing said its 3Q earnings increased to of $1.36 billion, or
$1.86 a share, buoyed by continued strong demand for the aerospace
giant's jetliners. Revenue climbed to $23.78 billion.
U.S. STOCKS TRADE LITTLE CHANGED
U.S. stocks traded little changed, pausing after a three-session
rally that carried the Dow back into positive territory for the
year. Stocks have whipsawed in past month amid threat of deflation
in Europe and worries about potential Fed policy changes.
U.S. CONSUMER PRICES UP 0.1%
The consumer-price index rose a seasonally adjusted 0.1% in
September from a month earlier. When excluding volatile food and
energy categories, prices also increased 0.1%. Economists had
forecast a 0.1% rise for both.
DOW CHEMICAL RESULTS TOP EXPECTATIONS
Dow Chemical, which has been selling off assets and streamlining
its operations, said its profit rose to $852 million, or 71c a
share, as sales thrived across the company's segments. Revenue rose
4.9% to $14.41 billion.
XEROX REVENUE EDGES DOWN 2.2%
Xerox said its 3Q revenue edged down 2.2% to $5.12 billion as
its document-technology business revenue continued to decline.
Overall, the company reported a profit of $266 million.
AMAZON'S TAX DEAL IN LUXEMBOURG
Amazon.com, whose tax arrangement with Luxembourg is being
investigated by the European Union, uses the tiny country as a
beachhead for its European operations and has a network of at least
10 Luxembourg units with about 1,000 employees in all.
GLAXO 3Q EARNINGS BEAT EXPECTATIONS
GlaxoSmithKline posted 3Q earnings that beat analysts'
expectations and announced a new cost-savings program and
management structure, as pressures in its U.S. business continue to
drag down sales and compound a tough year.
J&J TO TEST NEW EBOLA VACCINE ON HUMANS
Johnson & Johnson said it will begin testing an Ebola-virus
vaccine on humans in January and could have 250,000 doses available
in May.
TOTAL NAMES POUYANNÉ CEO
Total's board named refining and chemicals head Patrick Pouyanné
as its new CEO, installing a company veteran. Move follows the
death of Chairman and CEO Christophe de Margerie in a Moscow plane
crash Monday.
U.S. BANCORP RESULTS MEET EXPECTATIONS
U.S. Bancorp said it earned a little more than $1.47 billion in
the quarter as revenue increased 2% to $4.99 billion. The results
were in line with analysts' expectations.
BOSTON SCIENTIFIC SWINGS TO PROFIT
Boston Scientific swung to a profit of $43 million, or 3c a
share, from a year-earlier loss of $5 million, on higher sales in
cardiovascular and rhythm management segments. It also raised its
outlook for the year.
======= DOW JONES NEWSWIRES ANALYSIS AND COMMENTARIES =======
Grand Central
MORE ABOUT FED CULTURE CRACKDOWN ON BANKS
One day after New York Fed president berated Wall Street firms
for a loose culture that leads to bad behavior, a central bank
inspector general raised new questions about New York Fed's
willingness or ability to police them. Sign up here for The Wall
Street Journal's daily report on global central banks.
Analysis
WORLD BANK WARNS INDIA OF BUMPY RIDE AHEAD
As Reserve Bank of India gets the country ready to face the end
of the easy-money era, a World Bank paper looks back at how India
struggled a year ago -- and outlines a few tips to make the ride
smoother this time around.